Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
GENILGen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey. Address: Mustafa Kemal District 2119, Çankaya, Turkey, 06520
Analytics
WallStreetin tavoitehinta
4 331.95 TRYP/E-suhde
45.26Osinkotuotto
0.74 %Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut GENIL
Osinkoanalytiikka GENIL
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
21.00 %Osinkohistoria GENIL
Osakkeen arvostus GENIL
Talousasiat GENIL
Tuloksia | 2019 | Dynamiikka |